Mga Batayang Estadistika
| LEI | 549300AEUNO16KTJXD72 |
| CIK | 883975 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Microbot Medical Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission F |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission F |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission F |
|
| August 20, 2025 |
Exhibit 99.1 Microbot Medical® Granted U.S. Patent that Significantly Expands Potential Market Applications With the Newly Granted IP, the Company’s IP Portfolio for the LIBERTY® System now includes 12 patents granted globally and 57 patent applications pending. The Company Continues to Scale Commercial Readiness Plans for the LIBERTY® System as it Awaits FDA Decision. HINGHAM, Mass., August 20, 2 |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number: 000-19871 MICROBOT ME |
|
| August 12, 2025 |
Description of the Company’s Securities. Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the common stock of Microbot Medical Inc. (referred to as “the Company”, “we”, “us” and “our” unless specified otherwise) is based upon relevant provisions of the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of |
|
| August 5, 2025 |
Exhibit 99.1 Microbot Medical® Receives Non-Dilutive Grant to Enhance Operational Capabilities Strengthens Balance Sheet and Continues Commercialization Readiness Plans for the LIBERTY® System as it Nears FDA Marketing Clearance Decision HINGHAM, Mass., August 5, 2025 — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced it has been app |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 22, 2025 |
Exhibit 99.1 Microbot Medical® Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales Company Continues to Strengthen Organizational Infrastructure with Success-Driven Medical Device Veteran HINGHAM, Mass., July22, 2025 — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced the appointment of Christina Bailey a |
|
| July 21, 2025 |
As filed with the Securities and Exchange Commission on July 21, 2025 As filed with the Securities and Exchange Commission on July 21, 2025 Registration No. |
|
| July 21, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Microbot Medical Inc. |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 8, 2025 |
Exhibit 99.1 Microbot Medical® to Open Inaugural Endovascular Robotics Session at the Society of Robotic Surgery Annual Meeting Leading Endovascular Innovators to Highlight Emergence and Growth of Robotics in the Specialty HINGHAM, Mass., July 8, 2025 - Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced its participation in the inaugur |
|
| July 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission File |
|
| June 30, 2025 |
Exhibit 99.1 Microbot Medical® Added to the Russell Microcap® Index Automatic inclusion in the appropriate growth and value style indexes HINGHAM, Mass., June 30, 2025 — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced that it was added as a member of the Russell Microcap® Index. Microbot Medical’s addition will be effective today wh |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 17, 2025 |
Exhibit 99.1 Microbot Medical Strengthens Global IP Portfolio with Newly Granted Patent in China Significant Development Supports Long-Term Global Commercial Strategy of the LIBERTY® System HINGHAM, Mass., June 17, 2025 — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic System, announced that it has been granted a critical patent in China by the China |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 11, 2025 |
Certificate of Amendment to Certificate of Incorporation Exhibit 3.1 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF MICROBOT MEDICAL INC. Pursuant to § 242 of the General Corporation Law of the State of Delaware The undersigned, being the Chief Executive Officer of Microbot Medical Inc., a Delaware corporation (the “Corporation”), pursuant to Section 242 of the General Corporation Law of the State of Delaware, as amended (the “DGCL”), does |
|
| June 9, 2025 |
Exhibit 99.1 Microbot Medical Continues to Strengthen Commercial Capabilities in Preparation for the anticipated Q3 2025 Launch of its LIBERTY® Endovascular Robotic System The addition of the head of Sales Operations & Analytics aims to strengthen sales infrastructure and launch execution HINGHAM, Mass., June 9, 2025 – Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endov |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission File |
|
| June 5, 2025 |
Microbot Medical Selected for Preliminary Inclusion to Russell Microcap® Index Exhibit 99.1 Microbot Medical Selected for Preliminary Inclusion to Russell Microcap® Index HINGHAM, Mass., June 5, 2025 — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced that it has been selected for inclusion in the preliminary list of additions to the Russell Microcap® Index, as published by FTSE Russell on Friday, May 23, 2025. |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission File |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number: 000-19871 MICROBOT M |
|
| April 30, 2025 |
Exhibit 99.1 |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissions Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Stat |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissions Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat |
|
| April 23, 2025 |
Exhibit 99.1 Microbot Medical® Bolsters Commercial Leadership Team with the Addition of Experienced Healthcare Officers The addition of a seasoned VP of Marketing compliments the recent hiring of the Company’s VP of Sales to establish its commercialization readiness infrastructure Positive data from the recently published pivotal study raises confidence that LIBERTY® will be well received in the m |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissions Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 15, 2025 |
Exhibit 3.1 2.5. Quorum of Stockholders. At any meeting of the stockholders a quorum as to any matter shall consist of one-third of the votes entitled to be cast on the matter, except where a larger quorum is required by law, by the certificate of incorporation or by these by-laws. Any meeting may be adjourned from time to time by a majority of the votes properly cast upon the question, whether or |
|
| April 9, 2025 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 9, 2025 |
Exhibit 99.1 Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System Successful robotic navigation was achieved in every case and met the primary endpoint of the study LIBERTY® showed a 92% reduction in radiation exposure with no adverse events reported HINGHAM, Mass., April 9, 2025 — Microbot Medical |
|
| April 8, 2025 |
3,211,671 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-280113 PROSPECTUS 3,211,671 Shares of Common Stock This prospectus relates to the resale or other disposition from time to time of up to 3,211,671 shares of our common stock, $0.01 par value per share, by the selling stockholders named in this prospectus, including their transferees, pledgees, donees or successors, that may be issued |
|
| April 8, 2025 |
1,769,966 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-276487 PROSPECTUS 1,769,966 Shares of Common Stock This prospectus relates to the resale or other disposition from time to time of up to 1,769,966 shares of our common stock, $0.01 par value per share, by the selling stockholders named in this prospectus, including their transferees, pledgees, donees or successors, that may be issued |
|
| April 8, 2025 |
2,281,626 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-273207 PROSPECTUS 2,281,626 Shares of Common Stock This prospectus relates to the resale or other disposition from time to time of up to 2,281,626 shares of our common stock, $0.01 par value per share, by the selling stockholders named in this prospectus, including their transferees, pledgees, donees or successors, that may be issued |
|
| April 8, 2025 |
15,966,530 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-284688 PROSPECTUS 15,966,530 Shares of Common Stock This prospectus relates to the resale or other disposition from time to time of up to 15,966,530 shares of our common stock, $0.01 par value per share, by the selling stockholders named in this prospectus, including their transferees, pledgees, donees or successors, that may be issue |
|
| April 3, 2025 |
12,542,268 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-285690 PROSPECTUS 12,542,268 Shares of Common Stock This prospectus relates to the resale or other disposition from time to time of up to 12,542,268 shares of our common stock, $0.01 par value per share, by the selling stockholders named in this prospectus, including their transferees, pledgees, donees or successors, that may be issue |
|
| April 1, 2025 |
Exhibit 99.1 REMINDER: Microbot Medical Announces Data from the Company’s ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second Quarter BRAINTREE, Mass., April 1, 2025 - Microbot Medical Inc. (Nasdaq: MBOT), developer of |
|
| April 1, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 31, 2025 |
As filed with the Securities and Exchange Commission on March 31, 2025 As filed with the Securities and Exchange Commission on March 31, 2025 Registration No. |
|
| March 31, 2025 |
As filed with the Securities and Exchange Commission on March 31, 2025 As filed with the Securities and Exchange Commission on March 31, 2025 Registration No. |
|
| March 28, 2025 |
Microbot Medical Inc. 175 Derby St., Bld. 27 Hingham, MA 02043 Microbot Medical Inc. 175 Derby St., Bld. 27 Hingham, MA 02043 March 28, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. St., N.E. Washington, D.C. 20549 Re: Request for Acceleration of Effectiveness of Registration Statement on Form S-3 (File No. 333-285690) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amend |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 27, 2025 As filed with the Securities and Exchange Commission on March 27, 2025 Registration No. |
|
| March 27, 2025 |
As filed with the Securities and Exchange Commission on March 27, 2025 As filed with the Securities and Exchange Commission on March 27, 2025 Registration No. |
|
| March 27, 2025 |
As filed with the Securities and Exchange Commission on March 27, 2025 As filed with the Securities and Exchange Commission on March 27, 2025 Registration No. |
|
| March 27, 2025 |
As filed with the Securities and Exchange Commission on March 27, 2025 As filed with the Securities and Exchange Commission on March 27, 2025 Registration No. |
|
| March 25, 2025 |
Exhibit 19.2 Microbot Medical Inc. Insider Trading Policy March 25, 2025 I. Purpose This Insider Trading Policy (“Policy”) of Microbot Medical Inc. (together with its subsidiaries, the “Company”) sets forth the general standards for all employees, consultants, contractors, officers and directors with respect to engaging in transactions in Company securities and securities of other publicly traded |
|
| March 25, 2025 |
Blackout Period and Trading Window Policy Exhibit 19.1 MICROBOT MEDICAL INC. BLACKOUT PERIOD AND TRADING WINDOW POLICY This Blackout Period and Trading Window Policy (this “Policy”) is designed to supplement and complement the Corporate Code of Ethics and Conduct, as it may be amended or replaced from time to time (the “Code”) of Microbot Medical Inc. (the “Company”), including but not limited to Section 3.b of the Code relating to the Co |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number: 000-19871 MICROBOT MEDICAL |
|
| March 25, 2025 |
Exhibit 14.1 Microbot Medical Inc. Corporate Code of Ethics and Conduct 1. General Policy It has always been the policy of Microbot Medical Inc. and its subsidiaries (collectively, “Microbot” or the “Company”) to conduct business in compliance with all applicable laws, rules and regulations and with integrity. This is our obligation to our shareholders, to our community, to those government agenci |
|
| March 10, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Microbot Medical Inc. |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 4, 2025 |
Exhibit 99.1 Microbot Medical Appoints Seasoned Endovascular Sales Executive to Lead its U.S. Sales Activities for LIBERTY® Endovascular Robotic System Mr. Paul Mullen Most Recently Served as the Director of Sales at Inari Medical which was Acquired by Stryker Corporation Earlier This Year This Appointment Represents the Company’s First Commercial Hire as it Ramps Up Commercial Readiness in Antici |
|
| March 4, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissions Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| February 25, 2025 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| February 25, 2025 |
Exhibit 99.1 Robotic Telesurgery Data from Collaboration with Corewell Health™ Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting Research Collaboration demonstrates the feasibility of using the LIBERTY® Endovascular Robotic System between separate and remote facilities in a coronary simulation model BRAINTREE, Mass., February 25, 2025 — Microbot Medical Inc. (Nas |
|
| February 21, 2025 |
15,966,530 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-284688 PROSPECTUS 15,966,530 Shares of Common Stock This prospectus relates to the resale or other disposition from time to time of up to 15,966,530 shares of our common stock, $0.01 par value per share, by the selling stockholders named in this prospectus, including their transferees, pledgees, donees or successors, that may be issued upo |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| February 12, 2025 |
Microbot Medical Closes $13 Million Registered Direct Offering Exhibit 99.1 Microbot Medical Closes $13 Million Registered Direct Offering BRAINTREE, Mass., February 11, 2025 (GLOBE NEWSWIRE) - Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 6,103,289 shares of the Company’s common stock at a purchase price of $2.13 per |
|
| February 12, 2025 |
Microbot Medical Inc. 1,769,966 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-276487 PROSPECTUS SUPPLEMENT NO. 13 (To Prospectus dated June 21, 2024) Microbot Medical Inc. 1,769,966 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated June 21, 2024, as supplemented (the “Prospectus”), relating to the resale of up to 1,769,966 sh |
|
| February 12, 2025 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| February 12, 2025 |
Microbot Medical Inc. 3,211,671 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-280113 PROSPECTUS SUPPLEMENT NO. 13 (To Prospectus dated July 3, 2024) Microbot Medical Inc. 3,211,671 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated July 3, 2024, as supplemented (the “Prospectus”), relating to the resale or other disposition of |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| February 11, 2025 |
Exhibit 4.1 EXHIBIT A-2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFEC |
|
| February 11, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 11, 2025 |
Microbot Medical Inc. 288 Grove Street, Suite 388 Braintree, MA 02184 Microbot Medical Inc. 288 Grove Street, Suite 388 Braintree, MA 02184 February 11, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. St., N.E. Washington, D.C. 20549 Re: Request for Acceleration of Effectiveness of Registration Statement on Form S-1 (File No. 333-284688) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933 |
|
| February 11, 2025 |
MICROBOT MEDICAL INC. 6,103,289 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-275634 Prospectus Supplement (To Prospectus dated December 4, 2023) MICROBOT MEDICAL INC. 6,103,289 Shares of Common Stock We are offering 6,103,289 shares of our common stock, par value $0.01 per share (“common stock”) to investors at an offering price of $2.13 per share, pursuant to this prospectus supplement and the accompanying pr |
|
| February 11, 2025 |
Exhibit 99.1 Microbot Medical Announces $13 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules BRAINTREE, Mass., February 10, 2025 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 6,103,289 shares of the Company’s common stock at a purchase price of $2.13 per share of common s |
|
| February 11, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 9, 2025, between Microbot Medical Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| February 10, 2025 |
Microbot Medical Inc. 1,769,966 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-276487 PROSPECTUS SUPPLEMENT NO. 11 (To Prospectus dated June 21, 2024) Microbot Medical Inc. 1,769,966 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated June 21, 2024 as supplemented (the “Prospectus”), relating to the resale of up to 1,769,966 sha |
|
| February 10, 2025 |
Microbot Medical Inc. 1,769,966 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-276487 PROSPECTUS SUPPLEMENT NO. 12 (To Prospectus dated June 21, 2024) Microbot Medical Inc. 1,769,966 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated June 21, 2024, as supplemented (the “Prospectus”), relating to the resale of up to 1,769,966 sh |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| February 10, 2025 |
Microbot Medical Inc. 3,211,671 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-280113 PROSPECTUS SUPPLEMENT NO. 12 (To Prospectus dated July 3, 2024) Microbot Medical Inc. 3,211,671 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated July 3, 2024, as supplemented (the “Prospectus”), relating to the resale or other disposition of |
|
| February 10, 2025 |
Microbot Medical Inc. 3,211,671 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-280113 PROSPECTUS SUPPLEMENT NO. 11 (To Prospectus dated July 3, 2024) Microbot Medical Inc. 3,211,671 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated July 3, 2024, as supplemented (the “Prospectus”), relating to the resale or other disposition of |
|
| February 10, 2025 |
As filed with the Securities and Exchange Commission on February 10, 2025 As filed with the Securities and Exchange Commission on February 10, 2025 Registration No. |
|
| February 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| February 7, 2025 |
Exhibit 10.3 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment (this “Amendment”) to the Employment Agreement effective as of December 1, 2023 (the “Agreement”) by and between Microbot Medical Inc., a Delaware corporation, and Dr. Juan Diaz-Cartelle (the Executive”), is made as of the 5th day of February, 2025, by and between the Company and the Executive (capitalized terms used herein and not othe |
|
| February 7, 2025 |
Exhibit 10.1 ADDENDUM #2 TO EMPLOYMENT AGREEMENT made and entered into as of February 5, 2025 by and between Microbot Medical Ltd. Registration no. 514519412 of 6 Hayozma Street, Yokneam Illit, Israel (the “Company”) of the first part and Simon Sharon Israeli I.D no.27037753 of Israel (the “Employee”) of the second part WHEREAS, the Employee is employed by the Company in accordance with that certa |
|
| February 7, 2025 |
Exhibit 10.2 ADDENDUM TO EMPLOYMENT AGREEMENT made and entered into as of February 5, 2025 by and between Microbot Medical Ltd. Registration no. 514519412 of 6 Hayozma Street, Yokneam Illit, Israel (the “Company”) of the first part and Rachel Vaknin Israeli I.D no. 35883685 of Israel (the “Employee”) of the second part WHEREAS, the Employee is employed by the Company in accordance with that certai |
|
| February 4, 2025 |
As filed with the Securities and Exchange Commission on February 4, 2025 As filed with the Securities and Exchange Commission on February 4, 2025 Registration No. |
|
| February 4, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Microbot Medical Inc. |
|
| February 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| February 4, 2025 |
Exhibit 99.1 Microbot Medical® Announces Late-Breaking Abstract Acceptance at the Society of Interventional Radiology Annual Meeting Acceptance reflects the high interest of the SIR scientific committee on the emerging role of endovascular robotics BRAINTREE, Mass., February 4, 2025 — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today anno |
|
| February 3, 2025 |
Microbot Medical Inc. 1,769,966 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-276487 PROSPECTUS SUPPLEMENT NO. 10 (To Prospectus dated June 21, 2024) Microbot Medical Inc. 1,769,966 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated June 21, 2024 as supplemented (the “Prospectus”), relating to the resale of up to 1,769,966 sha |
|
| February 3, 2025 |
Microbot Medical Inc. 3,211,671 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-280113 PROSPECTUS SUPPLEMENT NO. 10 (To Prospectus dated July 3, 2024) Microbot Medical Inc. 3,211,671 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated July 3, 2024, as supplemented (the “Prospectus”), relating to the resale or other disposition of |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| January 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| January 21, 2025 |
Exhibit 99.1 Microbot Medical® Strengthens Its Management Team in Support of the Anticipated Commercial Launch of LIBERTY® Operations Leader to Enhance Operational Efficiencies by Managing Production Scale-up and Cost Reduction Activities to Support Commercialization BRAINTREE, Mass., January 21, 2025 - Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic |
|
| January 21, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| January 10, 2025 |
Exhibit 99.1 Microbot Medical Announces $8.6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules HINGHAM, Mass., January 8, 2025 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 3,788,550 shares of the Company’s common stock at a purchase price of $2.27 per share of common stoc |
|
| January 10, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 7, 2025, between Microbot Medical Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| January 10, 2025 |
MICROBOT MEDICAL INC. 3,788,550 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-275634 Prospectus Supplement (To Prospectus dated December 4, 2023) MICROBOT MEDICAL INC. 3,788,550 Shares of Common Stock We are offering 3,788,550 shares of our common stock, par value $0.01 per share (“common stock”) to investors at an offering price of $2.27 per share, pursuant to this prospectus supplement and the accompanying pr |
|
| January 10, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission F |
|
| January 10, 2025 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| January 10, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission F |
|
| January 7, 2025 |
MICROBOT MEDICAL INC. 4,000,001 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-275634 Prospectus Supplement (To Prospectus dated December 4, 2023) MICROBOT MEDICAL INC. 4,000,001 Shares of Common Stock We are offering 4,000,001 shares of our common stock, par value $0.01 per share (“common stock”) to institutional investors at an offering price of $1.75 per share, pursuant to this prospectus supplement and the a |
|
| January 7, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 6, 2025, between Microbot Medical Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| January 7, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 7, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 7, 2025 |
Exhibit 99.1 Microbot Medical Announces $7 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules HINGHAM, Mass., January 6, 2025 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 4,000,002 shares of the Company’s common stock at a purchase price of $1.75 per share of common stock |
|
| January 6, 2025 |
Microbot Medical Inc. 1,769,966 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-276487 PROSPECTUS SUPPLEMENT NO. 9 (To Prospectus dated June 21, 2024) Microbot Medical Inc. 1,769,966 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated June 21, 2024 as supplemented (the “Prospectus”), relating to the resale of up to 1,769,966 shar |
|
| January 6, 2025 |
Microbot Medical Inc. 3,211,671 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-280113 PROSPECTUS SUPPLEMENT NO. 9 (To Prospectus dated July 3, 2024) Microbot Medical Inc. 3,211,671 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated July 3, 2024, as supplemented (the “Prospectus”), relating to the resale or other disposition of |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission F |
|
| December 30, 2024 |
Exhibit 99.1 Microbot Medical® Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY® Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025 BRAINTREE, Mass., December 30, 2024 — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, concludes 2024 with the achievement of sev |
|
| December 30, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| December 10, 2024 |
Exhibit 99.1 Microbot Medical® Announces FDA Submission for the Commercialization of the LIBERTY® Endovascular Robotic System FDA 510(k) Submission Follows the Successful Completion of the Pivotal Human Clinical Trial FDA 510(k) Clearance Anticipated During the Second Quarter of 2025 Company Preparing to Commence Commercialization Following FDA 510(k) Clearance BRAINTREE, Mass., December 10, 2024 |
|
| December 10, 2024 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| December 10, 2024 |
Microbot Medical Inc. 1,769,966 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-276487 PROSPECTUS SUPPLEMENT NO. 8 (To Prospectus dated June 21, 2024) Microbot Medical Inc. 1,769,966 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated June 21, 2024 as supplemented (the “Prospectus”), relating to the resale of up to 1,769,966 shar |
|
| December 10, 2024 |
Microbot Medical Inc. 3,211,671 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-280113 PROSPECTUS SUPPLEMENT NO. 8 (To Prospectus dated July 3, 2024) Microbot Medical Inc. 3,211,671 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated July 3, 2024, as supplemented (the “Prospectus”), relating to the resale or other disposition of |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number: 000-19871 MICROB |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissions Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Stat |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissions Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat |
|
| October 31, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| October 31, 2024 |
Exhibit 99.1 |
|
| October 15, 2024 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| October 15, 2024 |
Microbot Medical Inc. 1,769,966 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-276487 PROSPECTUS SUPPLEMENT NO. 7 (To Prospectus dated June 21, 2024) Microbot Medical Inc. 1,769,966 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated June 21, 2024 as supplemented (the “Prospectus”), relating to the resale of up to 1,769,966 shar |
|
| October 15, 2024 |
Microbot Medical Inc. 3,211,671 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-280113 PROSPECTUS SUPPLEMENT NO. 7 (To Prospectus dated July 3, 2024) Microbot Medical Inc. 3,211,671 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated July 3, 2024, as supplemented (the “Prospectus”), relating to the resale or other disposition of |
|
| October 15, 2024 |
Exhibit 99.1 Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025 U.S. Food and Drug Administration (FDA) Submission Expected by end of 2024 Clinical Data to be Presented at Medical Conference in Early 2025 BRAINTREE, Mass., October 15, 2024 — Microbot Medical Inc. (Na |
|
| October 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission F |
|
| October 1, 2024 |
Microbot Medical Inc. 1,769,966 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-276487 PROSPECTUS SUPPLEMENT NO. 6 (To Prospectus dated June 21, 2024) Microbot Medical Inc. 1,769,966 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated June 21, 2024 as supplemented (the “Prospectus”), relating to the resale of up to 1,769,966 shar |
|
| October 1, 2024 |
Microbot Medical Inc. 3,211,671 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-280113 PROSPECTUS SUPPLEMENT NO. 6 (To Prospectus dated July 3, 2024) Microbot Medical Inc. 3,211,671 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated July 3, 2024, as supplemented (the “Prospectus”), relating to the resale or other disposition of |
|
| September 30, 2024 |
Exhibit 99.1 Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up Confirms the Company on Track for FDA 510(k) Submission by end of 2024 Completes All IDE required Tests and Receives Final IDE Approval from the FDA for the ACCESS-PVI Study BRAINTREE, Mass., September 3 |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commissio |
|
| September 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commissio |
|
| September 17, 2024 |
Exhibit 99.1 Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY® Endovascular Robotic Surgical System Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024 BRAINTREE, Mass., September 17, 2024 - Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIB |
|
| September 11, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commissio |
|
| September 11, 2024 |
Exhibit 99.1 |
|
| August 22, 2024 |
Microbot Medical Inc. 3,211,671 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-280113 PROSPECTUS SUPPLEMENT NO. 5 (To Prospectus dated July 3, 2024) Microbot Medical Inc. 3,211,671 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated July 3, 2024, as supplemented (the “Prospectus”), relating to the resale or other disposition of |
|
| August 22, 2024 |
Microbot Medical Inc. 1,769,966 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-276487 PROSPECTUS SUPPLEMENT NO. 5 (To Prospectus dated June 21, 2024) Microbot Medical Inc. 1,769,966 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated June 21, 2024 as supplemented (the “Prospectus”), relating to the resale of up to 1,769,966 shar |
|
| August 22, 2024 |
Exhibit 99.1 Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System The agreement follows the successful completion of Phase 1 which evaluated the viability of LIBERTY as a remote telesurgery platform The objective of Phase 2 is to develop and demonstrate new telesurgery capabilities by performing sim |
|
| August 22, 2024 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission F |
|
| August 15, 2024 |
Microbot Medical Inc. 1,769,966 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-276487 PROSPECTUS SUPPLEMENT NO. 4 (To Prospectus dated June 21, 2024) Microbot Medical Inc. 1,769,966 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated June 21, 2024 as supplemented (the “Prospectus”), relating to the resale of up to 1,769,966 shar |
|
| August 15, 2024 |
Microbot Medical Inc. 3,211,671 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-280113 PROSPECTUS SUPPLEMENT NO. 4 (To Prospectus dated July 3, 2024) Microbot Medical Inc. 3,211,671 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated July 3, 2024, as supplemented (the “Prospectus”), relating to the resale or other disposition of |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number: 000-19871 MICROBOT ME |
|
| August 13, 2024 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission F |
|
| August 13, 2024 |
Exhibit 99.1 Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization The ISO 13485 certification is a validation of the Company’s robust quality system BRAINTREE, Mass., August 13, 2024 — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces it has received ISO 13485:20 |
|
| August 13, 2024 |
Microbot Medical Inc. 3,211,671 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-280113 PROSPECTUS SUPPLEMENT NO. 3 (To Prospectus dated July 3, 2024) Microbot Medical Inc. 3,211,671 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated July 3, 2024, as supplemented (the “Prospectus”), relating to the resale or other disposition of |
|
| August 13, 2024 |
Microbot Medical Inc. 1,769,966 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-276487 PROSPECTUS SUPPLEMENT NO. 3 (To Prospectus dated June 21, 2024) Microbot Medical Inc. 1,769,966 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated June 21, 2024 as supplemented (the “Prospectus”), relating to the resale of up to 1,769,966 shar |
|
| August 13, 2024 |
Microbot Medical Inc. 1,005,965 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-277190 PROSPECTUS SUPPLEMENT NO. 6 (To Prospectus dated April 3, 2024) Microbot Medical Inc. 1,005,965 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated April 3, 2024, as supplemented (the “Prospectus”), relating to the resale of up to 1,005,965 sha |
|
| August 1, 2024 |
Exhibit 99.1 Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system BRAINTREE, Mass., August 1, 2024 — Microbot Medical Inc. (Nasdaq: MBOT) today announced it has entered into an |
|
| August 1, 2024 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 19, 2024 |
Microbot Medical Inc. 1,769,966 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-276487 PROSPECTUS SUPPLEMENT NO. 2 (To Prospectus dated June 21, 2024) Microbot Medical Inc. 1,769,966 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated June 21, 2024 as supplemented (the “Prospectus”), relating to the resale of up to 1,769,966 shar |
|
| July 19, 2024 |
Microbot Medical Inc. 3,211,671 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-280113 PROSPECTUS SUPPLEMENT NO. 2 (To Prospectus dated July 3, 2024) Microbot Medical Inc. 3,211,671 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated July 3, 2024, as supplemented (the “Prospectus”), relating to the resale or other disposition of |
|
| July 19, 2024 |
Microbot Medical Inc. 1,005,965 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-277190 PROSPECTUS SUPPLEMENT NO. 5 (To Prospectus dated April 3, 2024) Microbot Medical Inc. 1,005,965 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated April 3, 2024, as supplemented (the “Prospectus”), relating to the resale of up to 1,005,965 sha |
|
| July 18, 2024 |
Exhibit 99.1 Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center As the third and final clinical site, Memorial Sloan Kettering Cancer Center joins Brigham Women’s Hospital and Baptist Hospital of Miami as sites for the pivotal human clinical trial. BRAINTREE, Mass., July 18, 2024 — Microbot Med |
|
| July 18, 2024 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 10, 2024 |
3,211,671 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-280113 PROSPECTUS 3,211,671 Shares of Common Stock This prospectus relates to the resale or other disposition from time to time of up to 3,211,671 shares of our common stock, $0.01 par value per share, by the selling stockholders named in this prospectus, including their transferees, pledgees, donees or successors, that may be issued |
|
| July 9, 2024 |
Microbot Medical Inc. 1,769,966 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-276487 PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus dated June 21, 2024) Microbot Medical Inc. 1,769,966 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated June 21, 2024 (the “Prospectus”), relating to the resale of up to 1,769,966 shares of our common |
|
| July 9, 2024 |
Microbot Medical Inc. 1,005,965 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-277190 PROSPECTUS SUPPLEMENT NO. 4 (To Prospectus dated April 3, 2024) Microbot Medical Inc. 1,005,965 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated April 3, 2024, as supplemented (the “Prospectus”), relating to the resale of up to 1,005,965 sha |
|
| July 9, 2024 |
Exhibit 99.1 Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial Baptist Hospital of Miami is the second site to perform clinical procedures as part of the Company’s Pivotal Human Clinical Trial. The clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY® Endovascular Robotic Surgical System. BRAINTRE |
|
| July 9, 2024 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission File |
|
| July 9, 2024 |
Microbot Medical Inc. 3,211,671 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-280113 PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus dated July 3, 2024) Microbot Medical Inc. 3,211,671 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated July 3, 2024 (the “Prospectus”), relating to the resale or other disposition of up to 3,211,671 s |
|
| July 8, 2024 |
Exhibit 99.1 Microbot Medical Enrolled the First Patient in its Pivotal Human Clinical Trial The first clinical case was performed at Brigham and Women’s Hospital The clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY® Endovascular Robotic Surgical System BRAINTREE, Mass., July 8, 2024 — Microbot Medical Inc. (Nasdaq: MBOT) today announc |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission File |
|
| July 3, 2024 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission File |
|
| July 3, 2024 |
Exhibit 99.1 Microbot Medical Partners with Baptist Hospital of Miami to Participate in its Pivotal Human Clinical Trial Following the Company’s recent FDA approval to commence its pivotal human clinical trial, Baptist Hospital of Miami is the second clinical site to enroll in the trial BRAINTREE, Mass., July 3, 2024 — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endo |
|
| July 1, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission File |
|
| July 1, 2024 |
Exhibit 10.1 July 1, 2024 Microbot Medical Inc. 288 Grove Street, Suite 388 Braintree, MA 02184 Attention: Harel Gadot, President, CEO and Chairman Dear Mr. Gadot: Reference is made to the At The Market Offering Agreement, dated as of June 10, 2021 (the “ATM Agreement”), between Microbot Medical Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”). This letter (the “Amendment”) const |
|
| July 1, 2024 |
MICROBOT MEDICAL INC. Up to $4,819,905 of Common Stock PROSPECTUS SUPPLEMENT (to Prospectus dated December 4, 2023) Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| July 1, 2024 |
Microbot Medical Inc. 288 Grove Street, Suite 388 Braintree, MA 02184 July 1, 2024 Microbot Medical Inc. 288 Grove Street, Suite 388 Braintree, MA 02184 July 1, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. St., N.E. Washington, D.C. 20549 Re: Request for Acceleration of Effectiveness of Registration Statement on Form S-1 (File No. 333-280113) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as |
|
| June 20, 2024 |
As filed with the Securities and Exchange Commission on June 20, 2024 As filed with the Securities and Exchange Commission on June 20, 2024 Registration No. |
|
| June 17, 2024 |
Exhibit 99.1 Microbot Medical Announces Brigham and Women’s Hospital as a Site for its Pivotal Human Clinical Trial The Site Initiation Visit for the BWH clinical staff is complete and a shipment of LIBERTY investigational units was delivered BRAINTREE, Mass., June 17, 2024 — Microbot Medical Inc. (Nasdaq: MBOT) today announces that Brigham and Women’s Hospital (BWH), a leading academic medical ce |
|
| June 17, 2024 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 11, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Microbot Medical Inc. |
|
| June 11, 2024 |
As filed with the Securities and Exchange Commission on June 11, 2024 As filed with the Securities and Exchange Commission on June 11, 2024 Registration No. |
|
| June 11, 2024 |
As filed with the Securities and Exchange Commission on June 11, 2024 As filed with the Securities and Exchange Commission on June 11, 2024 Registration No. |
|
| June 4, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission File |
|
| June 4, 2024 |
EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 4, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 3, 2024, between Microbot Medical Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions se |
|
| June 4, 2024 |
Exhibit 99.1 Microbot Medical Announces $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules HINGHAM, Mass., June 3, 2024 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 1,566,669 shares of the Company’s common stock at a purchase price of $1.50 per share of common stock |
|
| June 4, 2024 |
MICROBOT MEDICAL INC. 1,566,669 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-275634 Prospectus Supplement (To Prospectus dated December 4, 2023) MICROBOT MEDICAL INC. 1,566,669 Shares of Common Stock We are offering 1,566,669 shares of our common stock, par value $0.01 per share (“common stock”) to institutional investors at an offering price of $1.50 per share, pursuant to this prospectus supplement and the a |
|
| June 4, 2024 |
Exhibit 99.2 Microbot Medical Announces Closing of $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules HINGHAM, Mass., June 4, 2024 (GLOBE NEWSWIRE) - Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,566,669 shares of the Com |
|
| June 3, 2024 |
Exhibit 99.1 Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial The trial will be conducted in the US and its results will complement the preclinical data on the LIBERTY® Endovascular Robotic Surgical System, which together are expected to support a future 510(k) submission. BRAINTREE, Mass., June 3, 2024 – Microbot Medical Inc. (Nasdaq: MBOT), developer of |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission File |
|
| June 3, 2024 |
As filed with the Securities and Exchange Commission on June 3, 2024 As filed with the Securities and Exchange Commission on June 3, 2024 Registration No. |
|
| May 16, 2024 |
Microbot Medical Inc. 1,005,965 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-277190 PROSPECTUS SUPPLEMENT NO. 3 (To Prospectus dated April 3, 2024) Microbot Medical Inc. 1,005,965 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated April 3, 2024, as supplemented (the “Prospectus”), relating to the resale of up to 1,005,965 sha |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number: 000-19871 MICROBOT M |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 29, 2024 |
Exhibit 99.1 Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™ The next step of the collaboration will explore potential future applications of the LIBERTY system, including its potential capabilities for remote endovascular procedures BRAINTREE, Mass., April 29, 2024 – Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBER |
|
| April 25, 2024 |
Microbot Medical Inc. 1,005,965 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333-277190 PROSPECTUS SUPPLEMENT NO. 2 (To Prospectus dated April 3, 2024) Microbot Medical Inc. 1,005,965 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated April 3, 2024, as supplemented (the “Prospectus”), relating to the resale of up to 1,005,965 sha |
|
| April 24, 2024 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 24, 2024 |
Exhibit 99.1 |
|
| April 16, 2024 |
Microbot Medical Inc. 1,005,965 Shares of Common Stock Filed pursuant to 424(b)(3) Registration Statement No. 333- 277190 PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus dated April 3, 2024) Microbot Medical Inc. 1,005,965 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated April 3, 2024 (the “Prospectus”), relating to the resale of up to 1,005,965 shares of our commo |
|
| April 15, 2024 |
Microbot Medical Shares Status Following Recent Geopolitical Events Exhibit 99.1 Microbot Medical Shares Status Following Recent Geopolitical Events All Regulatory, Clinical, Operational and Pre-Commercial Activities Continue to Stay on Track Despite the On-going Situation in Israel Company Believes that Both Regulatory and Commercial Milestones to be Achieved in Accordance with the Company’s Current Timeline BRAINTREE, Mass., April 15, 2024 – Microbot Medical Inc |
|
| April 15, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 4, 2024 |
1,005,965 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-277190 PROSPECTUS 1,005,965 Shares of Common Stock This prospectus relates to the sale or other disposition from time to time of up to 1,005,965 shares of our common stock, $0.01 par value per share, representing shares held by the selling stockholders named in this prospectus, including their transferees, pledgees, donees or successo |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration No. |
|
| April 1, 2024 |
Microbot Medical Inc. 288 Grove Street, Suite 388 Braintree, MA 02184 Microbot Medical Inc. 288 Grove Street, Suite 388 Braintree, MA 02184 April 1, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. St., N.E. Washington, D.C. 20549 Re: Request for Acceleration of Effectiveness of Registration Statement on Form S-1 (File No. 333-277190) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number: 000-19871 MICROBOT MEDICAL |
|
| March 27, 2024 |
Exhibit 97.1 MICROBOT MEDICAL INC. CLAWBACK POLICY A. Introduction The Board of Directors (the “Board”) of Microbot Medical Inc., a Delaware corporation (the “Company”) has adopted this policy (this “Policy”) to provide for the recovery or “clawback” of erroneously awarded incentive-based compensation from certain executive officers in accordance with Section 10D of the Securities Exchange Act of |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| February 20, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Microbot Medical Inc. |
|
| February 20, 2024 |
As filed with the Securities and Exchange Commission on February 20, 2024 As filed with the Securities and Exchange Commission on February 20, 2024 Registration No. |
|
| February 14, 2024 |
MBOT / Microbot Medical Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 30, 2024 |
Exhibit 10.1 SETTLEMENT AGREEMENT AND RELEASE This Settlement Agreement and Release (the “Agreement”) is made and entered into this 26th day of January, 2024 (the “Effective Date”), by and between Empery Asset Master Ltd., Empery Tax Efficient, LP, Empery Tax Efficient III, LP (“Empery”) and Hudson Bay Master Fund Ltd. (“Hudson Bay” together with Empery, “Plaintiffs”) on the one hand and Microbot |
|
| January 30, 2024 |
1,769,966 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-276487 PROSPECTUS 1,769,966 Shares of Common Stock This prospectus relates to the sale or other disposition from time to time of up to 1,769,966 shares of our common stock, $0.01 par value per share, representing shares issuable upon the exercise of outstanding preferred investment options held by the selling stockholders named in thi |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| January 30, 2024 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 26, 2024, between Microbot Medical Inc., a Delaware corporation (the “Company”), and each of the several entities signatory hereto (each such entity, a “Plaintiff” and, collectively, the “Plaintiffs”). This Agreement is made pursuant to the Settlement Agreement an |
|
| January 30, 2024 |
Exhibit 99.1 Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters All of the cash payable to the plaintiffs in the settlement will be covered by Microbot’s insurance carrier and will not impact company’s cash position BRAINTREE, Mass., January 30, 2024 – Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascula |
|
| January 23, 2024 |
Microbot Medical Inc. 288 Grove Street, Suite 388 Braintree, MA 02184 Microbot Medical Inc. 288 Grove Street, Suite 388 Braintree, MA 02184 January 23, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. St., N.E. Washington, D.C. 20549 Re: Request for Acceleration of Effectiveness of Registration Statement on Form S-1 (File No. 333-276487) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, |
|
| January 22, 2024 |
Form of Inducement Investment Option Exhibit 4.11 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| January 22, 2024 |
Exhibit 10.32 MICROBOT MEDICAL INC. December 29, 2023 Holder of Preferred Investment Options Issued in October 2022 and June 2023 Re: Inducement Offer to Exercise Preferred Investment Options Issued in October 2022 and June 2023 Dear Holder: Microbot Medical Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) the opportunity to receive (a) new preferred investm |
|
| January 22, 2024 |
Form of Placement Agent Investment Option Exhibit 4.12 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| January 22, 2024 |
As filed with the Securities and Exchange Commission on January 22, 2024 As filed with the Securities and Exchange Commission on January 22, 2024 Registration No. |
|
| January 18, 2024 |
Exhibit 99.1 Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study Following the recent positive results of its pivotal GLP pre-clinical study, the Company added a CRA to facilitate the company’s first in human clinical study BRAINTREE, Mass., January 18, 2023 – Microbot Medical Inc. (Nasdaq: MBOT), developer of |
|
| January 18, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| January 12, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Microbot Medical Inc. |
|
| January 12, 2024 |
As filed with the Securities and Exchange Commission on January 12, 2024 As filed with the Securities and Exchange Commission on January 12, 2024 Registration No. |
|
| January 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission F |
|
| January 2, 2024 |
Exhibit 99.1 Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules BRAINTREE, Mass., Dec. 29, 2023 — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced the entry into a definitive agreement for the immediate exercise of |
|
| January 2, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 2, 2024 |
2,281,626 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-273207 PROSPECTUS SUPPLEMENT (To Prospectus dated July 17, 2023) 2,281,626 Shares of Common Stock Under that certain prospectus, dated July 17, 2023 (the “Prospectus”), filed on July 18, 2023 pursuant to Rule 424(b)(3), as part of our registration statement on Form S-1 (File No. 333-273207), as amended on July 14, 2023 and declared effective on |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| January 2, 2024 |
Exhibit 10.1 MICROBOT MEDICAL INC. December 29, 2023 Holder of Preferred Investment Options Issued in October 2022 and June 2023 Re: Inducement Offer to Exercise Preferred Investment Options Issued in October 2022 and June 2023 Dear Holder: Microbot Medical Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) the opportunity to receive (a) new preferred investme |
|
| January 2, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 14, 2023 |
Exhibit 99.1 Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for Telerobotic The first phase in the collaboration will evaluate the current state of the LIBERTY® Robotic Surgical System in connection with remote enabled Endovascular treatments. BRAINTREE, Mass., December 14, 2023 – Microbot Medical Inc. (Nasdaq: MBOT), develop |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| December 7, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| December 7, 2023 |
Exhibit 99.1 Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study The final histopathology and lab report supplements previous positive Company findings. The results of the study will support the Company’s IDE submission to the FDA to commence its human clinical study BRAINTREE, Mass |
|
| December 1, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| December 1, 2023 |
Microbot Medical Inc. 288 Grove Street, Suite 388 Braintree, MA 02184 Microbot Medical Inc. 288 Grove Street, Suite 388 Braintree, MA 02184 December 1, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. St., N.E. Washington, D.C. 20549 Re: Request for Acceleration of Effectiveness of Registration Statement on Form S-3 (File No. 333-275634) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, |
|
| November 30, 2023 |
As filed with the Securities and Exchange Commission on November 30, 2023 As filed with the Securities and Exchange Commission on November 30, 2023 Registration No. |
|
| November 21, 2023 |
Exhibit 10.1 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (the “Agreement”), effective as of December 1, 2023 (the “Effective Date”), by and between Microbot Medical Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), and Dr. Juan Diaz-Cartelle (the “Executive”). WITNESSETH: WHEREAS, the Company is desirous of securing the Executive’s services and the E |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| November 21, 2023 |
Exhibit 99.1 Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz-Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities The former Senior Medical Director for the Peripheral Interventions Division at Boston Scientific Corporation joins the Company as it transitions to the clinical and regulatory phase. BRAINTREE, Mass., November |
|
| November 17, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Microbot Medical Inc. |
|
| November 17, 2023 |
Exhibit 4.4 MICROBOT MEDICAL INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5.04 |
|
| November 17, 2023 |
As filed with the Securities and Exchange Commission on November 17, 2023 As filed with the Securities and Exchange Commission on November 17, 2023 Registration No. |
|
| November 17, 2023 |
Form of Subordinated Indenture Exhibit 4.5 MICROBOT MEDICAL INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c) |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number: 000-19871 MICROB |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| November 13, 2023 |
Exhibit 99.1 Microbot Medical Successfully Completed Integral Part of the Verification and Validation Process The V&V process is an additional key milestone toward regulatory submission and is required to continue the regulatory process with the FDA BRAINTREE, Mass., November 13, 2023 – Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Robotic Surgical System, today announ |
|
| November 8, 2023 |
Microbot Medical Granted Registered Trademark from The U.S. Patent and Trademark Office Exhibit 99.1 Microbot Medical Granted Registered Trademark from The U.S. Patent and Trademark Office BRAINTREE, Mass., November 8, 2023 – Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system, today announced it had been granted a registered trademark from the US Patent and Trademark Office. The trademark “One |
|
| November 8, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| November 6, 2023 |
Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission |
|
| October 31, 2023 |
Exhibit 99.1 Microbot Medical Reveals Successful Short Term Follow Up Outcomes from its Pivotal Pre-Clinical Study Follow up visual examination three days after the procedures using the LIBERTY Robotic Surgical System, confirms 100% success rate in reaching the targets with no adverse events. BRAINTREE, Mass., October 31, 2023 – Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIB |
